News
Media
Conference
Publications
Resources
Partners
Subscribe

Spotlight -

Geographic Atrophy

Opinion|Videos|February 7, 2025

Safety Profile of New Therapies

Author(s)John Kitchens, MD, Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth, Michael W. Stewart, MD

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.

Episodes in this series

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP. 2 Advantages of the molecular structure of aflibercept

EP. 2 Advantages of the molecular structure of aflibercept

EP. 3 Treat-and-Extend Strategy With Aflibercept

EP. 3 Treat-and-Extend Strategy With Aflibercept

EP. 4 Assessing New Therapies for Retinal Diseases

EP. 4 Assessing New Therapies for Retinal Diseases

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP. 7 Patient Selection for Aflibercept 8 mg

EP. 7 Patient Selection for Aflibercept 8 mg

EP. 8 Faricimab Molecular Design and Role of Ang-2

EP. 8 Faricimab Molecular Design and Role of Ang-2

EP. 9 Outcomes with Faricimab and Choosing Between the New Therapies

EP. 9 Outcomes with Faricimab and Choosing Between the New Therapies

EP. 10 Safety Profile of New Therapies

EP. 11 Perspectives on the Usefulness of Real-world Data

EP. 11 Perspectives on the Usefulness of Real-world Data

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

Based on the clinical trial data, how do you view the safety profiles of faricimab and aflibercept 8 mg?
Does the long-term safety profile of aflibercept 2 mg increase your confidence in the safety of aflibercept 8 mg?
Does the increased volume of aflibercept 8 mg raise concerns about the potential for elevated intraocular pressure? How do you evaluate and address this in clinical practice?

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Related Content

(Image credit: Modern Retina) Retina World Congress 2026: Identifying real-world durability gaps in wet AMD treatment

Retina World Congress 2026: Identifying real-world durability gaps in wet AMD treatment

ByPatricio G. Schlottmann, MD,Sheryl Stevenson

May 16th 2026

(Image credit: AdobeStock/Maris Maskalans) Retina World Congress 2026: Can vibration reduce pain during intravitreal injections?

Retina World Congress 2026: Can vibration reduce pain during intravitreal injections?

ByVictor M. Villegas, MD,Sheryl Stevenson

May 16th 2026

(Image credit: AdobeStock/ANASTASIIA) Retina World Congress 2026: The case for earlier surgical intervention in diabetic macular edema

Retina World Congress 2026: The case for earlier surgical intervention in diabetic macular edema

ByMatias Iglicki, MD, PhD,Sheryl Stevenson

May 15th 2026

(Image credit: AdobeStock/BazziBa) Beyond anti-VEGF: The next wave in retinal therapy

Beyond anti-VEGF: The next wave in retinal therapy

ByMark R. Barakat, MD

May 4th 2026

(Image credit: Modern Retina/Ophthalmology Times)

Eichenbaum Acorns: Paying it forward with Christina Y. Weng, MD, MBA, FASRS

ByDavid A. Eichenbaum, MD, FASRS,Christina Y. Weng, MD, MBA, FASRS

April 22nd 2026

Latest CME

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

David A. Eichenbaum, MD

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

Nathan C. Steinle, MD

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

Tanner Ferguson, MD; Taj Nasser, MD, FWCRS

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

David A. Eichenbaum, MD

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

Nathan C. Steinle, MD

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

Tanner Ferguson, MD; Taj Nasser, MD, FWCRS

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Trending on Modern Retina

Retina World Congress 2026: Identifying real-world durability gaps in wet AMD treatment

Retina World Congress 2026: Rethinking macular hole surgery without gas tamponade

Retina World Congress 2026: Diagnosing macular telangiectasia in a field of mimickers

Retina World Congress 2026: The case for earlier surgical intervention in diabetic macular edema

Retina World Congress 2026: Sunir J. Garg, MD, FACS, on preventing occupational injury in retina practice